Department of Dermatology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, China.
Department of Dermatology, Hubei Provincial Hospital TCM, Wuhan, China.
J Food Biochem. 2019 Nov;43(11):e13032. doi: 10.1111/jfbc.13032. Epub 2019 Sep 9.
This animal experiment was framed to evaluate the beneficial effect of ginsenoside Rg1 (GRg1) against imiquimod (IMQ)-induced psoriasis-like dermatitis model to reveal the underpinning mechanism. Fifty healthy BALB/c mice were divided into five groups as control, GRg1, IMQ induced, oral treatment of GRg1 (50 mg/kg), or dexamethasone (DXM; 10 mg/kg) in IMQ-induced mice. Treatment with GRg1 or DXM significantly mitigates (p < .01) psoriasis area severity index (PASI) score, skin thickness, lipid peroxidation, and inflammatory markers (IL-23, 22, 17A, 1β, and TNF-α). Moreover, administration of GRg1 or DXM considerably reversed the morphological changes induced by IMQ with improved (p < .01) antioxidant activity (SOD, CAT). In addition, a marked downregulation (p < .01) of protein expressions of pIκB and NF-κB p65 (NF-κB signaling pathway) were noted in GRg1 group. Collectively, GRg1 or DXM treatment significantly abolishes IMQ-induced psoriasis-like dermatitis by lowering PASI score, inflammation through downregulating NF-κB signaling pathway. PRACTICAL APPLICATIONS: This is the very first study to explore the efficacy of ginsenoside Rg1 (GRg1) against IMQ-induced psoriasis in the mice model to reveal the underpinning mechanism. The results clearly showed that GRg1 potent anti-psoriasis activity by lowering PASI score, inflammation through downregulating NF-κB signaling pathway. Hence, this study helps in the development of novel nutraceutical/functional food against psoriasis and thus could improve the quality of life in psoriasis patients. However, further clinical trials are needed to justify the above results before developing a commercial functional food using GRg1 against psoriasis.
这项动物实验旨在评估人参皂苷 Rg1（GRg1）对咪喹莫特（IMQ）诱导的银屑病样皮炎模型的有益作用，以揭示其潜在机制。将 50 只健康 BALB/c 小鼠分为五组：对照组、GRg1 组、IMQ 诱导组、GRg1（50mg/kg）口服治疗组和 IMQ 诱导组中的地塞米松（DXM；10mg/kg）组。GRg1 或 DXM 的治疗显著减轻（p<.01）银屑病面积严重程度指数（PASI）评分、皮肤厚度、脂质过氧化和炎症标志物（IL-23、22、17A、1β 和 TNF-α）。此外，GRg1 或 DXM 的给药极大地逆转了 IMQ 诱导的形态变化，改善了（p<.01）抗氧化活性（SOD、CAT）。此外，GRg1 组中 pIκB 和 NF-κB p65（NF-κB 信号通路）的蛋白表达显著下调（p<.01）。总之，GRg1 或 DXM 治疗通过降低 PASI 评分、通过下调 NF-κB 信号通路来减轻炎症，显著消除了 IMQ 诱导的银屑病样皮炎。
这是第一项研究探索人参皂苷 Rg1（GRg1）对咪喹莫特（IMQ）诱导的小鼠模型中银屑病的疗效，以揭示其潜在机制。结果清楚地表明，GRg1 通过降低 PASI 评分、通过下调 NF-κB 信号通路来减轻炎症，具有强大的抗银屑病活性。因此，这项研究有助于开发针对银屑病的新型营养/功能性食品，从而提高银屑病患者的生活质量。然而，在开发使用 GRg1 治疗银屑病的商业功能性食品之前，还需要进一步的临床试验来证实上述结果。
